Every material Form 8-K Harmony Biosciences Holdings filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Harmony Biosciences reported third-quarter 2025 net product revenue of $239.5 million, up 29% from $186.0 million a year earlier, and GAAP net income of $50.9 million, or $0.87 per diluted share, versus $0.79 a year earlier. The company raised its full-year 2025 net product revenue guidance to $845-$865 million from $820-$860 million, though its research and development expenses rose 117% to $55.0 million, including a $15.0 million charge tied to a ZYN002 milestone.
Q3 2025 net product revenue of $239.5 million, up from $186.0 million in Q3 2024
GAAP net income of $50.9 million, or $0.87 per diluted share, versus $0.79 in Q3 2024
2025 net product revenue guidance raised to $845-$865 million from $820-$860 million
ZYN002 phase 3 RECONNECT study in Fragile X syndrome missed its primary endpoint; the 22q11.2 deletion syndrome program is paused
Harmony Biosciences said preliminary third-quarter 2025 net revenue for the WAKIX franchise was about $239 million, up 29% year over year, and raised its 2025 revenue guidance to $845 million-$865 million from $820 million-$860 million. The figures are preliminary and unaudited, and the company will report full third-quarter results on November 4, 2025.
WAKIX franchise net revenue of about $239 million in Q3 2025, up 29% year over year
Average patients reached 8,100 in Q3 2025, an increase of about 500 for the quarter
2025 revenue guidance raised to $845 million-$865 million from $820 million-$860 million
Results are preliminary and unaudited; full Q3 2025 results and conference call set for November 4, 2025
Harmony Biosciences reported second-quarter 2025 net product revenue of $200.5 million, up 16% from $172.8 million a year earlier, and GAAP net income of $39.8 million, or $0.68 per diluted share, compared with $11.6 million, or $0.20, in Q2 2024. The company reaffirmed its full-year 2025 net product revenue guidance of $820 million to $860 million, so higher sales and profit were reported with the annual forecast unchanged.
Q2 2025 net product revenue was $200.5 million, up from $172.8 million; average patients rose by 400 to 7,600
GAAP diluted EPS was $0.68 versus $0.20 in Q2 2024; non-GAAP adjusted diluted EPS was $0.92 versus $0.43
Full-year 2025 net product revenue guidance reaffirmed at $820 million to $860 million
Cash, cash equivalents and investments were $672.3 million as of June 30, 2025; Fragile X Phase 3 topline data expected in Q3 2025
Harmony Biosciences reported first-quarter 2025 results, with WAKIX net product revenue of $184.7 million, up 20% from $154.6 million a year earlier, and GAAP net income of $45.6 million, or $0.78 per diluted share, versus $0.67 a year earlier. The company reaffirmed its full-year 2025 net product revenue guidance of $820 million to $860 million, and the filing also includes an investor presentation posted to its website.
Q1 2025 net product revenue $184.7 million, up 20% from $154.6 million in Q1 2024
GAAP net income $45.6 million, or $0.78 per diluted share, versus $0.67 in Q1 2024
Full-year 2025 net product revenue guidance of $820 million to $860 million reaffirmed, not changed
Total operating expenses rose 29% to $96.5 million, led by a 56% rise in R&D to $34.5 million; cash and investments were $610.2 million at March 31, 2025
Harmony Biosciences appointed Ron Philip, chief executive of Orbital Therapeutics, as a Class III director effective April 2, 2025, filling a vacancy left by Jack Bech Nielsen's June 2024 resignation. The filing describes him as independent and says he will join the Audit Committee and Nominating and Corporate Governance Committee effective April 7, 2025. The appointment is a board governance change and contains no financial results, guidance or deal terms.
Ron Philip, age 51, appointed Class III director effective April 2, 2025
Joins Audit Committee and Nominating and Corporate Governance Committee effective April 7, 2025
Board determined Philip is independent under Nasdaq and SEC standards
Previously served as CEO of Spark Therapeutics from April 2022 to September 2024
Harmony Biosciences said Chief Commercial Officer Jeffrey Dierks is leaving for personal reasons, effective March 31, 2025, and named Adam Zaeske, formerly a senior executive at Takeda Pharmaceuticals, as his successor on the same date. Dierks's separation agreement provides a $476,215 lump-sum payment and accelerated vesting of part of his equity awards. The company's CEO said the company remains confident in its 2025 revenue guidance.
Jeffrey Dierks departs as Chief Commercial Officer effective March 31, 2025, for personal reasons
Separation agreement dated March 20, 2025 provides a $476,215 lump-sum payment and accelerated vesting of awards for the portion that would have vested in calendar 2025
Adam Zaeske becomes Executive Vice President and Chief Commercial Officer effective March 31, 2025; he previously served as Senior Vice President at Takeda Pharmaceuticals from April 2022 to March 2025
CEO Jeffrey Dayno said the company remains confident in its 2025 revenue guidance
Harmony Biosciences reported fourth-quarter and full-year 2024 results, with WAKIX net product revenue of $201.3 million for the quarter, up 20% from a year earlier, and $714.7 million for the year, up 23%. The company reiterated its 2025 WAKIX net revenue guidance of $820 million to $860 million and said it reached a settlement in its first generic patent litigation. Quarterly GAAP diluted earnings per share were $0.85, up from $0.45, while full-year 2024 GAAP diluted EPS was $2.51, up from $2.13.
Q4 2024 net product revenue was $201.3 million, compared with $168.4 million in Q4 2023.
Q4 2024 GAAP net income was $49.5 million, or $0.85 per diluted share, versus $26.6 million, or $0.45, a year earlier.
Full-year 2024 net product revenue was $714.7 million; 2025 WAKIX net revenue guidance is $820 million to $860 million, reiterated, not changed.
Full-year 2024 GAAP net income was $145.5 million, or $2.51 per diluted share, including a $25.5 million upfront licensing fee and a $17.1 million IPR&D charge within R&D expenses.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Harmony Biosciences Holdings filing is on SEC EDGAR ↗. 8-K briefs of other companies →